Potential Risks and Benefits of GLP-1 Medications

Fox News senior medical analyst Dr. Marc Siegel discusses a University of California San Diego study on GLP-1 weight loss medications and their influence on biological aging. He highlights cardiovascular and neurological benefits while drawing attention to potential digestive and thyroid-related side effects.

Study Findings and Concerns

Research has brought to light a possible link between GLP-1 medications and Wernicke encephalopathy, a rare but serious neurological disorder. The study published in Clinical Nutrition identified 15 cases linked to GLP-1 receptor agonists such as semaglutide and tirzepatide. These cases were reviewed through the FDA’s Adverse Event Reporting System, medical literature, and a medical center’s records.

Risk Factors and Symptoms

Patients reported symptoms like weight loss, vomiting, loss of appetite, or malnutrition. Vitamin B1 deficiency, potentially exacerbated by these medications, is suspected to be the cause. B1 deficiencies can lead to confusion, balance and vision issues, and in severe cases, neurological damage or death.

Expert Opinions

Karthik Achari, not involved in the study, emphasizes the rarity of these cases among millions of GLP-1 users. However, he acknowledges the seriousness and plausible mechanism of these effects, noting that GLP-1 drugs can decrease appetite, increasing the risk of vitamin B1 deficiency.

Nutritionist Erin Palinski-Wade advises incorporating proper nutrition and hydration into treatment plans. She warns that reduced appetite can lead to under-eating essential nutrients, and continuous gastrointestinal issues might pose risks of dehydration and kidney problems. Symptoms should be addressed medically if they persist.

Final Thoughts and Further Research

While the study cannot conclusively link GLP-1 medications to Wernicke encephalopathy, further research is encouraged. Patients should consult healthcare providers before making any changes to their prescribed medication regimen.